Description
Stanozolol (Winstrol, Winny) is a synthetic dihydrotestosterone derivative with pyrazole ring fusion at the A-ring and 17α-methyl group. The pyrazole modification makes Stanozolol resistant to 5α-reduction and aromatization, yielding a sharp DHT profile without estrogen action.
Per study reports Stanozolol binds to the androgen receptor with moderate affinity. The missing aromatization means no water retention - on the contrary, many customers observe a “drying-out” action with reduced subcutaneous water retention. This makes Winstrol the classical cutting compound of anabolic research practice.
Pharmacokinetically orally bioavailable with about 9-hour half-life. Steady-state within 2-3 days. The oral variant has a second unusual property: Stanozolol lowers SHBG levels markedly, raising the free fraction of other anabolics in the stack.
Stanozolol became famous in 1988 when Ben Johnson tested positive for the substance after his Olympic 100m sprint victory. Clinically Winstrol was approved for treatment of hereditary angioedema and in veterinary medicine.
Known effects in studies: high hepatotoxicity (one of the most hepatotoxic anabolics overall), joint dryness and pain (frequently reported in recreational practice), unfavorable lipid profile with strong HDL drop, HPG suppression. Joint effects presumably stem from the strong DHT action without estrogen protection.
Stanozolol is on the WADA banned list.
You can order Stanozolol as oral tablets in one bottle with 50mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Stanozolol is among the most hepatotoxic anabolics overall and therefore sits clearly in the upper range of the risk scale. The effects documented in the literature primarily affect the liver, lipid profile and joints.
Documented in studies and the user literature:
- High liver strain: as a 17α-methyl steroid, Stanozolol is strongly hepatotoxic and is one of the most liver-toxic members of the class, documented in several hepatotoxicity studies.
- Lipid profile: studies describe an unfavorable lipid profile with a pronounced HDL drop.
- Joint effects: joint dryness and pain are frequently reported in the user literature, presumably due to the strong DHT action without estrogen protection.
- Suppression of natural production: suppression of the HPG axis is documented, and Stanozolol additionally lowers SHBG levels markedly.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Hereditary angioedema: Safety of long-term stanozolol therapy - Journal of Allergy and Clinical Immunology 2007, Sloane et al: Long-term safety study of prophylactic stanozolol therapy in hereditary angioedema.
- Hereditary angioedema: A decade of management with stanozolol - Journal of Allergy and Clinical Immunology 1987, Sheffer et al: Clinical ten-year follow-up on efficacy and side effects.
- Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema - Journal of Allergy and Clinical Immunology 1980, Agostoni et al: Comparative study of prophylactic therapy in HAE.
- Effect of Stanozolol on Liver Function - JAMA 1963: Early study on hepatic function parameters under stanozolol.
- Hepatotoxicity Associated with Methylstenbolone and Stanozolol Abuse - Medical Journal of Clinical Trials and Case Studies 2018, Vargas et al: Case series on liver damage under stanozolol abuse.
